Why the study?
Do triglyceride-lowering agents reduce cardiovascular risk in statin-treated patients?
Do triglyceride-lowering agents reduce cardiovascular risk in statin-treated patients?
While triglyceride-lowering agents have shown inconsistent cardiovascular outcomes, eicosapentaenoic acid may reduce coronary events in statin-treated patients.
EPA may inform selective use in statin-treated patients; leaves open class effects for other triglyceride-lowering agents.
Cardiovascular (CV) risk remains in some patients who are treated with statins. Evidence supports a role for triglycerides (TGs) in CV disease. TG-lowering agent outcomes studies have been inconsistent, but eicosapentaenoic acid significantly reduced coronary events in hypercholesterolemic patients who were treated with statins. Ongoing outcomes studies will clarify the role of TG-lowering treatments in CV risk reduction.
No takes yet. Share an insight, caveat, or question.
Copple et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: